Outlook Therapeutics (OTLK) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OTLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTLK, but not buy additional shares or sell existing shares.
View OTLK analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month price objectives for Outlook Therapeutics' stock. Their OTLK share price forecasts range from $1.00 to $10.00. On average, they anticipate the company's share price to reach $4.83 in the next year. This suggests a possible upside of 2,213.7% from the stock's current price.
View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts.

Outlook Therapeutics' stock was trading at $1.08 on January 1st, 2023. Since then, OTLK stock has decreased by 80.7% and is now trading at $0.2089.
View the best growth stocks for 2023 here.

Outlook Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 26,660,000 shares, an increase of 52.3% from the August 15th total of 17,510,000 shares. Based on an average daily volume of 5,130,000 shares, the days-to-cover ratio is presently 5.2 days. Currently, 21.1% of the company's shares are sold short.
View Outlook Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our OTLK earnings forecast.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.04.

Outlook Therapeutics's stock reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.59%), State Street Corp (1.07%), Geode Capital Management LLC (1.06%), Northern Trust Corp (0.49%), Nuveen Asset Management LLC (0.23%) and Nuveen Asset Management LLC (0.23%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Syntone Ventures Llc, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OTLK stock can currently be purchased for approximately $0.21.

Outlook Therapeutics (NASDAQ:OTLK) has a market capitalization of $54.36 million.

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.outlooktherapeutics.com. The company can be reached via phone at (609) 619-3990 or via email at jeremy@lifesciadvisors.com.